Statins inhibit endogenous cholesterol production by competitive inhibition of HMG-CoA reductase (HMGCR), the enzyme that catalyzes conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. This pathway delineates genes involved in statin pharmacogenomics, including genes involved in mediating the effects of statins on plasma lipoprotein metabolism. Sources: [https://www.pharmgkb.org/do/serve?objId=PA2031&objCls=Pathway PharmGKB] and [http://en.wikipedia.org/wiki/Statin Wikipedia]

Authors

Thomas Kelder , Alex Pico , Daniela Digles , Martina Summer-Kutmon , Egon Willighagen , and Eric Weitz

Cited In

• 

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organism

Bos taurus

Communities

Annotations

Cell Type Ontology: hepatocyte

Disease Ontology: cardiovascular system disease

Pathway Ontology: statin drug pathway

Participants

References

1. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997 Apr 1;1345(2):136–50. PubMed Europe PMC Scholia
2. Chen H, Ikeda U, Shimpo M, Shimada K. Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res. 2000 Mar;23(2):187–92. PubMed Europe PMC Scholia